- Home
- SDHY vs FTRE Comparison
SDHY vs FTRE Comparison
Compare SDHY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- FTRE
- Stock Information
- Founded
- SDHY 2020
- FTRE 1996
- Country
- SDHY United States
- FTRE United States
- Employees
- SDHY N/A
- FTRE N/A
- Industry
- SDHY Finance/Investors Services
- FTRE Medical Specialities
- Sector
- SDHY Finance
- FTRE Health Care
- Exchange
- SDHY Nasdaq
- FTRE Nasdaq
- Market Cap
- SDHY 400.4M
- FTRE 469.0M
- IPO Year
- SDHY N/A
- FTRE N/A
- Fundamental
- Price
- SDHY $16.48
- FTRE $5.32
- Analyst Decision
- SDHY
- FTRE Hold
- Analyst Count
- SDHY 0
- FTRE 11
- Target Price
- SDHY N/A
- FTRE $17.10
- AVG Volume (30 Days)
- SDHY 94.0K
- FTRE 2.7M
- Earning Date
- SDHY 01-01-0001
- FTRE 08-11-2025
- Dividend Yield
- SDHY 8.46%
- FTRE N/A
- EPS Growth
- SDHY N/A
- FTRE N/A
- EPS
- SDHY 1.07
- FTRE N/A
- Revenue
- SDHY N/A
- FTRE $2,685,600,000.00
- Revenue This Year
- SDHY N/A
- FTRE N/A
- Revenue Next Year
- SDHY N/A
- FTRE $1.36
- P/E Ratio
- SDHY $14.31
- FTRE N/A
- Revenue Growth
- SDHY N/A
- FTRE N/A
- 52 Week Low
- SDHY $13.93
- FTRE $3.97
- 52 Week High
- SDHY $15.50
- FTRE $28.41
- Technical
- Relative Strength Index (RSI)
- SDHY 61.59
- FTRE 49.95
- Support Level
- SDHY $16.22
- FTRE $3.97
- Resistance Level
- SDHY $16.53
- FTRE $6.56
- Average True Range (ATR)
- SDHY 0.11
- FTRE 0.49
- MACD
- SDHY 0.01
- FTRE 0.10
- Stochastic Oscillator
- SDHY 75.55
- FTRE 52.12
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.